Sarepta Therapeutics, Inc. (NASDAQ:SRPT) CFO Sandesh Mahatme sold 50,000 shares of Sarepta Therapeutics stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total value of $2,050,000.00. Following the completion of the transaction, the chief financial officer now owns 41,736 shares in the company, valued at $1,711,176. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) traded down 0.46% during trading on Friday, hitting $36.70. The company’s stock had a trading volume of 1,272,093 shares. The firm’s 50 day moving average price is $37.48 and its 200-day moving average price is $33.08. The company’s market cap is $2.36 billion. Sarepta Therapeutics, Inc. has a 52 week low of $24.96 and a 52 week high of $63.73.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.46. The firm had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. During the same period in the prior year, the business earned ($1.19) earnings per share. The company’s revenue for the quarter was up 350000.0% on a year-over-year basis. On average, analysts predict that Sarepta Therapeutics, Inc. will post ($1.16) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was first posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/08/19/insider-selling-sarepta-therapeutics-inc-srpt-cfo-sells-50000-shares-of-stock-updated-updated-updated.html.
A number of institutional investors have recently made changes to their positions in SRPT. Prentiss Smith & Co. Inc. increased its position in shares of Sarepta Therapeutics by 772.2% in the second quarter. Prentiss Smith & Co. Inc. now owns 3,576 shares of the biotechnology company’s stock valued at $121,000 after buying an additional 3,166 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at about $127,000. PNC Financial Services Group Inc. increased its position in shares of Sarepta Therapeutics by 150.1% in the first quarter. PNC Financial Services Group Inc. now owns 4,666 shares of the biotechnology company’s stock valued at $138,000 after buying an additional 2,800 shares in the last quarter. Cubist Systematic Strategies LLC increased its position in shares of Sarepta Therapeutics by 116.4% in the second quarter. Cubist Systematic Strategies LLC now owns 4,600 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,474 shares in the last quarter. Finally, Edge Wealth Management LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at about $175,000. 63.11% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have commented on the company. BidaskClub cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. William Blair reaffirmed an “outperform” rating on shares of Sarepta Therapeutics in a report on Thursday, July 27th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price target on shares of Sarepta Therapeutics in a report on Friday, June 30th. Zacks Investment Research upgraded Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, Robert W. Baird reiterated an “outperform” rating and set a $102.00 price objective on shares of Sarepta Therapeutics in a research note on Wednesday, July 12th. Eight equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Sarepta Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $61.28.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
What are top analysts saying about Sarepta Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sarepta Therapeutics Inc. and related companies.